A major Lancet meta-analysis reported that most side effects commonly attributed to statins are not supported by strong evidence, with only a few rare risks confirmed and the cardiovascular...
In a recent Pitt Med feature, CP3’s Dr. Tom Radomski reflects on his journey from student to Associate Director of the Institute for Clinical Research Education (ICRE) at the University of Pittsburgh...
CP3 Director Dr. Walid Gellad will moderate a panel titled “Focus on Non-Government Payers” at the upcoming conference Novel Solutions to Address the Rising Cost of Oncology Drugs: Targeting the...
Two CP3 faculty affiliates, Dr. Sarah Belcher and Dr. Luke Berenbrok, were recently highlighted in the Pitt Research Annual Report for work that advances medication use and patient care. Dr. Belcher’s...
We are excited to start the year by planning to share our risk prediction work at two upcoming conferences the UPMC Digital Health Summit and theCollege on Problems of Drug Dependence's (CPDD)...
CP3’s own Dr. Tim Anderson was interviewed for a New York Times story examining recent trends in the use of GLP-1 weight-loss medications among older adults and the factors driving changes in patient...
Congratulations to Yujin Seo, a doctoral student from CMU who is working with CP3’s Dr. Katie Suda on her Drug Shortages project. Yujin presented at the IQVIA Institute Research Forum in September...
CP3's Dr. Luke Berenbrok spoke with Newsweek about ways that Medicare users can ensure they are using all of their benefits, especially those for OTC items. He suggests talking with community...
A new Ars Technica piece highlights work by CP3’s Dr. Tim Anderson, showing that GLP-1 drugs improve heart health, but benefits fade when treatment stops—raising important questions about long-term...
CP3 Associate Director Dr. Katie Suda was interviewed for Dr. Bicuspid on the risks of prescribing opioids to pediatric patients. Results of a recent study published in JADA "emphasize the need for...
